Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

194 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
ABL-class Genomic Breakpoint Q-PCR: A Patient-specific Approach for MRD Monitoring in Acute Lymphoblastic Leukemia.
van Outersterp I, van der Velden VHJ, Hoogeveen PG, Vaitkevičienė GE, Sonneveld E, van Haaften G, Kuiper RP, Zur Stadt U, Escherich G, Boer JM, den Boer ML. van Outersterp I, et al. Among authors: boer jm, den boer ml. Hemasphere. 2023 Sep 19;7(10):e967. doi: 10.1097/HS9.0000000000000967. eCollection 2023 Oct. Hemasphere. 2023. PMID: 37736661 Free PMC article. No abstract available.
Immunobiological diversity in infant acute lymphoblastic leukemia is related to the occurrence and type of MLL gene rearrangement.
Jansen MW, Corral L, van der Velden VH, Panzer-Grümayer R, Schrappe M, Schrauder A, Marschalek R, Meyer C, den Boer ML, Hop WJ, Valsecchi MG, Basso G, Biondi A, Pieters R, van Dongen JJ. Jansen MW, et al. Among authors: den boer ml. Leukemia. 2007 Apr;21(4):633-41. doi: 10.1038/sj.leu.2404578. Epub 2007 Feb 1. Leukemia. 2007. PMID: 17268512
High expression of CD40 on B-cell precursor acute lymphoblastic leukemia blasts is an independent risk factor associated with improved survival and enhanced capacity to up-regulate the death receptor CD95.
Troeger A, Glouchkova L, Ackermann B, Escherich G, Meisel R, Hanenberg H, den Boer ML, Pieters R, Janka-Schaub GE, Goebel U, Laws HJ, Dilloo D. Troeger A, et al. Among authors: den boer ml. Blood. 2008 Aug 15;112(4):1028-34. doi: 10.1182/blood-2007-11-123315. Epub 2008 Jun 13. Blood. 2008. PMID: 18552209 Free article.
Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol.
Van der Velden VH, Corral L, Valsecchi MG, Jansen MW, De Lorenzo P, Cazzaniga G, Panzer-Grümayer ER, Schrappe M, Schrauder A, Meyer C, Marschalek R, Nigro LL, Metzler M, Basso G, Mann G, Den Boer ML, Biondi A, Pieters R, Van Dongen JJ; Interfant-99 Study Group. Van der Velden VH, et al. Among authors: den boer ml. Leukemia. 2009 Jun;23(6):1073-9. doi: 10.1038/leu.2009.17. Epub 2009 Feb 12. Leukemia. 2009. PMID: 19212338 Clinical Trial.
The long-term impact of in vitro drug sensitivity on risk stratification and treatment outcome in acute lymphoblastic leukemia of childhood (CoALL 06-97).
Escherich G, Tröger A, Göbel U, Graubner U, Pekrun A, Jorch N, Kaspers G, Zimmermann M, zur Stadt U, Kazemier K, Pieters R, Den Boer ML, Horstmann M, Janka GE; CoALL study group, Hamburg, Germany. Escherich G, et al. Among authors: den boer ml. Haematologica. 2011 Jun;96(6):854-62. doi: 10.3324/haematol.2010.039735. Epub 2011 Feb 17. Haematologica. 2011. PMID: 21330320 Free PMC article.
Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium.
Zwaan CM, Rizzari C, Mechinaud F, Lancaster DL, Lehrnbecher T, van der Velden VH, Beverloo BB, den Boer ML, Pieters R, Reinhardt D, Dworzak M, Rosenberg J, Manos G, Agrawal S, Strauss L, Baruchel A, Kearns PR. Zwaan CM, et al. Among authors: den boer ml. J Clin Oncol. 2013 Jul 1;31(19):2460-8. doi: 10.1200/JCO.2012.46.8280. Epub 2013 May 28. J Clin Oncol. 2013. PMID: 23715577 Clinical Trial.
Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL.
van der Veer A, Waanders E, Pieters R, Willemse ME, Van Reijmersdal SV, Russell LJ, Harrison CJ, Evans WE, van der Velden VH, Hoogerbrugge PM, Van Leeuwen F, Escherich G, Horstmann MA, Mohammadi Khankahdani L, Rizopoulos D, De Groot-Kruseman HA, Sonneveld E, Kuiper RP, Den Boer ML. van der Veer A, et al. Among authors: den boer ml. Blood. 2013 Oct 10;122(15):2622-9. doi: 10.1182/blood-2012-10-462358. Epub 2013 Aug 23. Blood. 2013. PMID: 23974192 Free PMC article.
194 results